Third Rock's $40M bet on Blueprint's rapid quest to personalise cancer therapies
This article was originally published in Scrip
Executive Summary
"Our vision is to transform certain cancers into manageable conditions." So says, founding president and CEO of Blueprint Medicines, Chris Varma.